MARC details
000 -LÍDER |
fixed length control field |
03389nam a22004815i 4500 |
001 - NÚMERO DE CONTROL |
control field |
u372521 |
003 - IDENTIFICADOR DEL NÚMERO DE CONTROL |
control field |
SIRSI |
005 - FECHA Y HORA DE LA ULTIMA TRANSACCIÓN |
control field |
20160812084102.0 |
007 - CAMPO FIJO DE DESCRIPCIÓN FIJA--INFORMACIÓN GENERAL |
fixed length control field |
cr nn 008mamaa |
008 - ELEMENTOS DE LONGITUD FIJA -- INFORMACIÓN GENERAL |
fixed length control field |
100722s2010 xxu| s |||| 0|eng d |
020 ## - NÚMERO INTERNACIONAL NORMALIZADO PARA LIBROS |
International Standard Book Number |
9781603272711 |
-- |
978-1-60327-271-1 |
040 ## - FUENTE DE CATALOGACIÓN |
Transcribing agency |
MX-MeUAM |
050 #4 - SIGNATURA TOPOGRÁFICA DE LA BIBLIOTECA DEL CONGRESO |
Classification number |
RC261-271 |
082 04 - NÚMERO DE CLASIFICACIÓN DECIMAL DEWEY |
Classification number |
614.5999 |
Edition number |
23 |
100 1# - ASIENTO PRINCIPAL--NOMBRE PERSONAL |
Personal name |
Polunovsky, Vitaly A. |
Relator term |
editor. |
245 10 - MENCIÓN DE TITULO |
Title |
mTOR Pathway and mTOR Inhibitors in Cancer Therapy |
Medium |
[recurso electrónico] / |
Statement of responsibility, etc. |
edited by Vitaly A. Polunovsky, Peter J. Houghton. |
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
Place of production, publication, distribution, manufacture |
Totowa, NJ : |
Name of producer, publisher, distributor, manufacturer |
Humana Press : |
-- |
Imprint: Humana Press, |
Date of production, publication, distribution, manufacture, or copyright notice |
2010. |
300 ## - DESCRIPCIÓN FÍSICA |
Extent |
XII, 304 p. |
Other physical details |
online resource. |
336 ## - CONTENT TYPE |
Content type term |
text |
Content type code |
txt |
Source |
rdacontent |
337 ## - MEDIA TYPE |
Media type term |
computer |
Media type code |
c |
Source |
rdamedia |
338 ## - CARRIER TYPE |
Carrier type term |
online resource |
Carrier type code |
cr |
Source |
rdacarrier |
347 ## - DIGITAL FILE CHARACTERISTICS |
File type |
text file |
Encoding format |
PDF |
Source |
rda |
490 1# - MENCIÓN DE SERIE |
Series statement |
Cancer Drug Discovery and Development |
505 0# - NOTA DE CONTENIDO |
Formatted contents note |
mTORC1: A Signaling Integration Node Involved in Cell Growth -- The Regulation of the IGF-1/mTOR Pathway by the p53 Tumor Suppressor Gene Functions -- mTOR Signaling in Angiogenesis -- mTORC1 Signaling and Hypoxia -- mTOR Signaling in Glioblastoma: Lessons Learned from Bench to Bedside -- mTOR and Cancer Therapy: General Principles -- mTOR and Cancer Therapy: Clinical Development and Novel Prospects -- Drug Combinations as a Therapeutic Approach for mTORC1 Inhibitors in Human Cancer -- Downstream Targets of mTORC1 -- Downstream of mTOR: Translational Control of Cancer -- Genome-Wide Analysis of Translational Control -- Translational Control of Cancer: Implications for Targeted Therapy -- Downstream from mTOR: Therapeutic Approaches to Targeting the eIF4F Translation Initiation Complex. |
520 ## - NOTA DE RESUMEN, ETC. |
Summary, etc. |
mTOR Pathway and mTOR Inhibitors in Cancer Therapy provides an up-to-date survey of the rapidly advancing field of cancer therapy. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment – targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. In this work, experts in TOR signaling have contributed in two thematic areas: mTOR Signaling and Cancer Therapy (chapters 1 - 8) and Therapeutic Targeting Downstream of mTOR (chapter 9 – 13). All chapters of mTOR Pathway and mTOR Inhibitors in Cancer Therapy are completely new or have been extensively updated by their authors; and we are indebted to all authors who have exemplified the links between these 2 thematic areas. |
596 ## - |
-- |
19 |
650 #0 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO |
Topical term or geographic name as entry element |
Medicine. |
650 #0 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO |
Topical term or geographic name as entry element |
Oncology. |
650 #0 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO |
Topical term or geographic name as entry element |
Toxicology. |
650 #0 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO |
Topical term or geographic name as entry element |
Cytology. |
650 14 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO |
Topical term or geographic name as entry element |
Biomedicine. |
650 24 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO |
Topical term or geographic name as entry element |
Cancer Research. |
650 24 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO |
Topical term or geographic name as entry element |
Cell Biology. |
650 24 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO |
Topical term or geographic name as entry element |
Pharmacology/Toxicology. |
700 1# - ASIENTO SECUNDARIO - NOMBRE PERSONAL |
Personal name |
Houghton, Peter J. |
Relator term |
editor. |
710 2# - ASIENTO SECUNDARIO - NOMBRE CORPORATIVO |
Corporate name or jurisdiction name as entry element |
SpringerLink (Online service) |
773 0# - HOST ITEM ENTRY |
Title |
Springer eBooks |
776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
Relationship information |
Printed edition: |
International Standard Book Number |
9781603272704 |
830 #0 - ASIENTO SECUNDARIO DE SERIE--TITULO UNIFORME |
Uniform title |
Cancer Drug Discovery and Development |
856 40 - LOCALIZACIÓN Y ACCESO ELECTRÓNICOS |
Public note |
Libro electrónico |
Uniform Resource Identifier |
<a href="http://148.231.10.114:2048/login?url=http://link.springer.com/book/10.1007/978-1-60327-271-1">http://148.231.10.114:2048/login?url=http://link.springer.com/book/10.1007/978-1-60327-271-1</a> |
942 ## - TIPO DE MATERIAL (KOHA) |
Koha item type |
Libro Electrónico |